Chief Revenue Officer
Ronnie O’Dell
United States
Ronnie leads revenue strategy and growth for Upper Echelon Management. He brings more than 25 years of experience building regulated distribution, channel, vendor-network, and go-to-market systems.
About UEM
Pharmaceutical launch experience, built into an accountable commercialization system.
Upper Echelon Management combines pharmaceutical commercial leadership with regulated distribution and go-to-market systems experience. That operating foundation informs both client work and the development of RxLaunchOS.
Experience · Evidence · Accountable decisions
Multidisciplinary by design
Different disciplines should not all look—or think—the same.
The UEM operating model is designed to connect senior science, commercial, market access, field, distribution, and program leaders around the same launch evidence.
Specialists enter with a defined scope: contribute the judgment the decision needs, make assumptions visible, and leave the manufacturer with a clearer path forward.
The UEM team
Founding experience inside a multidisciplinary operating team.
UEM brings revenue leadership, pharmaceutical commercialization experience, and a broader team of operators and specialists to each engagement. Team members enter according to the decision, evidence, and functional depth required—not as a generic bench assigned to every project.
Founder · Since 2015
Sharon O’Dell
United States
Sharon began her pharmaceutical career in 1996 after earning a Bachelor of Science in History, magna cum laude, from UC Berkeley. Her career progressed through Janssen Pharmaceuticals, Bristol Myers Squibb, Sankyo—where she accepted her first district manager position—Novo Nordisk, VIVUS, and Amplity, where she served as National Sales Director. She has helped launch several pharmaceutical products during her career.
Managing Partner, Advanced Metabolic & Obesity Practice
Alexandra “Alex” Cortez
Virginia, USA
Advanced metabolic and obesity launch architecture, retention strategy, and cross-functional commercial design.
Partner, Launch Architecture & U.S. Entry Practice
Kenji Nakamura
Tokyo, Japan
U.S. market-entry planning, launch architecture, segmentation, and field-model design for global manufacturers.
Partner, Talent Architecture & Field Excellence
Mei Lin
Shenzhen, China
Commercial organization design, selection frameworks, field-team readiness, and manager development.
Partner, Real-World Retention & Access Strategy
Diego Alvarez
Bogotá, Colombia
Real-world evidence, outcomes, payer dynamics, patient access, and persistence strategy.
Director, Clinical Operations & Patient Support Design
Sophia Gallagher, RN, MSN
London, United Kingdom
Patient-support design, nurse-liaison models, onboarding pathways, and clinical program operations.
Practice leaders & senior consultants
Specialist depth aligned to the work.
The wider team spans field strategy, market access, evidence, clinical operations, finance, analytics, training, organizational readiness, and cross-border U.S. entry.
Daniel “Danny” Brooks
Compliance & Risk-Informed Design
Washington, D.C., USA
Ethan Carter
Commercial Finance & Launch Economics
Chicago, USA
Jing Chen
Real-World Evidence & Outcomes Integration
Shanghai, China
Priya Desai
Omnichannel & Patient Experience
Mumbai, India
Rafael “Rafa” Jiménez
KOL & Speaker Program Strategy
Houston, USA
Marcus Lee
Field Analytics & Performance Optimization
Seoul, South Korea
Luis Martinez
Field Strategy & Squad Deployment
Miami, USA
Claudia Morales, RN, MSN
Nurse Liaison & Patient Support Models
San Antonio, USA
Christopher “Chris” O’Neill
Access & Channel Strategy
Paris, France
Naomi Park
Pricing & Contracting Strategy
Seoul, South Korea
Marisol Reyes
Training & New Manager Development
Mexico City, Mexico
Isabella “Bella” Ruiz
Cardiometabolic Portfolio Strategy
Milan, Italy
Yuki Sato
Medical-Commercial Interface
Osaka, Japan
Hiroko Tan
U.S. Market Entry & Partner Models
Frankfurt, Germany
Emily Watson
Organizational Change & Launch Readiness
Basel, Switzerland
The standard
Commercial judgment should get stronger when it enters a system.
Evidence before certainty
Separate what is known, assumed, inferred, and still missing. Confidence should never outrun the evidence supporting it.
Methodology must be inspectable
Commercial logic should be versioned, configurable, explainable, and open to operator and expert challenge—not buried in software or a slide deck.
Expertise belongs at the decision
Use specialists where their judgment changes the decision, with clear scope, sourcing, and disclosure of limitations or conflicts.
The manufacturer remains accountable
UEM provides operating leverage and decision clarity. It does not outsource leadership accountability or pretend an advisor owns the launch.
A boundary we state plainly
No team covers every launch discipline.
UEM's founding experience includes pharmaceutical commercial leadership, organization, field execution, hiring, and regulated commercial systems. The broader team adds other operator and specialist perspectives as each decision requires.
Deep payer and market-access expertise is a specialist requirement, not a claim we manufacture. UEM's model is designed to bring qualified experts into those decisions with explicit scope and evidence.
Discuss the expertise your decision requires